Mechanisms of Ferroptosis and Emerging Links to the Pathology of Neurodegenerative Diseases

Yiyan Sun1†, Xiaohuan Xia1,2,3,4†, Diksha Basnet1, Jialin C. Zheng2,3,4,5*, Jian Huang6* and Jianhui Liu1*

1 Department of Anesthesiology, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai, China, 2 Center for Translational Neurodegeneration and Regenerative Therapy, Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai, China, 3 Shanghai Frontiers Science Center of Nanocatalytic Medicine, Shanghai, China, 4 Translational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People’s Hospital Affiliated to Tongji University School of Medicine, Shanghai, China, 5 Collaborative Innovation Center for Brain Science, Tongji University, Shanghai, China, 6 Key Laboratory of Systems Biomedicine (Ministry of Education) and Collaborative Innovation Center of Systems Biomedicine, Shanghai Center for Systems Biomedicine, Shanghai Jiao Tong University, Shanghai, China

Neurodegenerative diseases are a diverse class of diseases attributed to chronic progressive neuronal degeneration and synaptic loss in the brain and/or spinal cord, including Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, amyotrophic lateral sclerosis and multiple sclerosis. The pathogenesis of neurodegenerative diseases is complex and diverse, often involving mitochondrial dysfunction, neuroinflammation, and epigenetic changes. However, the pathogenesis of neurodegenerative diseases has not been fully elucidated. Recently, accumulating evidence revealed that ferroptosis, a newly discovered iron-dependent and lipid peroxidation-driven type of programmed cell death, provides another explanation for the occurrence and progression of neurodegenerative diseases. Here, we provide an overview of the process and regulation mechanisms of ferroptosis, and summarize current research progresses that support the contribution of ferroptosis to the pathogenesis of neurodegenerative diseases. A comprehensive understanding of the emerging roles of ferroptosis in neurodegenerative diseases will shed light on the development of novel therapeutic technologies and strategies for slowing down the progression of these diseases.

Keywords: ferroptosis, neurodegenerative diseases, iron metabolism, oxidative stress, redox regulation

INTRODUCTION

Dolma et al. (2003) discovered a new mechanism of cell death using a small molecule called erastin. In 2012, Scott Dixon discovered that erastin caused a non-apoptotic form of cell death with unique morphological, biochemical, and genetic properties, which was later termed ferroptosis (Dixon et al., 2012). As our knowledge of cell death continues to be updated, the concepts and mechanisms of ferroptosis are further elucidated. In 2018, the Nomenclature Committee on Cell Death defined ferroptosis as a Regulated Cell Death (RCD) caused by oxidative distress in the intracellular microenvironment, which can be inhibited by lipophilic antioxidants and iron chelators (Galluzzi et al., 2018). Recently, numerous studies have shown that ferroptosis is closely related to various diseases,
including tumors (Mou et al., 2019), neurological disorders (Ren et al., 2020), metabolic diseases (Le et al., 2021), and cardiovascular diseases (Yu et al., 2021). Neurodegenerative diseases (NDDs) are a group of diseases characterized by the progressive loss of a specific population of neurons, resulting in progressive cognitive decline, movement impairment, and other comorbidities, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and so on (Wells et al., 2019). Ferroptosis has been proven to be closely correlated with the occurrence and development of most NDDs. Here, we introduce the molecular mechanism of ferroptosis, the contribution of ferroptosis to the pathogenesis of NDDs, and the potential value of targeting ferroptosis in the treatment of NDDs.

**THE PROCESS AND REGULATION OF FERROPTOSIS**

**The Process of Ferroptosis**

As an independent form of cell death, ferroptosis can be clearly distinguished from other forms of cell death by the accumulation of lethal reactive oxygen species (ROS) and lipid peroxidation products caused by iron-dependent reactions (Table 1; Dixon et al., 2012; Wu et al., 2012; Liu and Levine, 2015; Chen et al., 2016; Xie et al., 2016; Galluzzi et al., 2017; D’Arcy, 2019; Xu et al., 2019; Demarco et al., 2020; Mizushima and Levine, 2020; Nah et al., 2020; Khan et al., 2021; Li et al., 2021; Nadeem et al., 2021; Yang et al., 2021; Braicu et al., 2022; Lei et al., 2022). Ultrastructural changes in mitochondria are the most prominent morphological features of ferroptotic cells. Overall, the process of ferroptosis consists of multiple key steps including iron metabolism dysregulation and lipid peroxidation (Figure 1).

**Iron Metabolism**

Iron overload caused by intracellular iron metabolism disorder is an important factor that induces ferroptosis. The cellular iron metabolism involves regulation of iron absorption, storage, utilization, excretion, and some special cell iron regulatory elements.

**Cellular Iron Absorption, Storage, and Excretion**

Iron is internalized through diet absorption by duodenal enterocytes into the bloodstream (Winter et al., 2014). The circulating iron levels can be further regulated by tissue macrophages that engulf senescent red blood cells to release iron via ferroportin (FPN) (Winter et al., 2014). Cellular iron absorption involves the following pathways: (1) Transferrin-bound iron (TBI) pathway refers to that circulating iron binds to transferrin (Tf) and is recognized by the transferrin receptors bound iron (TBI) pathway refers to that circulating iron binds to transferrin (Tf) and is recognized by the transferrin receptors (TfR1, TfR2). Iron enters cells primarily via receptor-mediated endocytosis. TfRs are internalized through diet absorption by duodenal enterocytes into the bloodstream (Winter et al., 2014). The iron is internalized through diet absorption by duodenal enterocytes into the bloodstream (Winter et al., 2014). Cellular iron internalization through diet absorption by duodenal enterocytes into the bloodstream (Winter et al., 2014). Upon cleavage in the cytoplasm by heme oxygenase 1 (HO-1), free iron is available as NTBI (Mizushima and Levine, 2008). Iron metabolism dysregulation and lipid peroxidation (Masaldan et al., 2019). Increased cellular iron absorption, weakened iron storage capacity, or blocked iron excretion, will finally lead to an abnormal accumulation of iron and possible ferroptosis.

**Labile Iron Pool**

Small amounts of iron exist in the free state to form the cellular labile iron pool (LIP), also considered as the cellular chelatable pool or the redox-active iron complex pool (Kakhlon and Cabanthik, 2002). Free iron in LIP is mainly found in free ferrous iron, which can bind to various ligand groups and transported by iron chaperones, as poly(rC)-binding protein 1 (PCBP1), mediate binding to iron-requiring or iron-containing proteins and enzymes, enabling cells to meet their metabolic needs for iron (Lv and Shang, 2018; Philpott et al., 2020). LIP is homeostatic to other forms of intracellular iron regulation, while minimizing its involvement in the formation hydroxyl radicals (OH·) from hydrogen peroxide (H2O2), further reducing the occurrence of cytotoxic chemical reactions in intracellular oxygen-rich environments (Lv and Shang, 2018).

**Mitochondrial Iron**

Mitochondria are critical sites for iron utilization and accumulation. Cytoplasmic ferrous iron can be imported...
| Ferroptosis | Apoptosis | Autophagy | Necroptosis | Pyroptosis |
|-------------|-----------|-----------|-------------|------------|
| **Morphological features** | | | | |
| Cell morphology | Smaller and rounder; cell rounding up | Shrinkage; intercellular connections disappear | Minor changes | Swelling; formed bubble-like protrusions |
| Cell membrane | No rupture or blistering | Plasma membrane blebbing; membrane structure remains intact | Blebbing sometimes observed | Rupture of plasma membrane |
| Cytoplasm | Small mitochondria with condensed mitochondrial membrane densities | Retraction of pseudopods; dense cellular contents | Vacuolization of the cytoplasm; accumulation of double-membraned autophagic vacuoles | Cytoplasmic swelling, swelling of cytoplasmic organelles |
| Nucleus | Normal nuclear size; lack of chromatin condensation | Genetic materials fragmentation; marked chromatin condensation; nuclear fragmentation and condensation | Lack of chromatin condensation | Mild-moderate chromatin condensation (Nuclear pyknosis) |
| Special features | Mitochondrial atrophy or fragmentation; mitochondrial membrane density condensed; mitochondrial cristae decreased | Apoptotic bodies (or ApoBDs) | Numerous autophagosomes and autolysosomes | Necrotic bodies |
| Biological features | Iron and ROS accumulation; lipid peroxides increased; system Xc⁻ and GPX4 inhibition; GSH depletion; Δψm dissipation | Caspase activation; DNA fragmentation; Δψm dissipation; intracellular calcium increased | LC3-I to LC3-II conversion; ATG expression increased; increased lysosomal activity | Activation of RIP1, RIP3, and MLKL; PARP1 hyperactivation; drop in ATP levels |
| Immunological features | Release of DAMPs (e.g., inflammatory factor, arachidonic acid mediators, HMGB1) | Release Ecto-CRT, Histone, HMGB1, and ATP under certain conditions | Regulation of immune cell differentiation and function | Release of DAMPs (e.g., DNA, IL-6 and HMGB1) |
| Main inducer and inhibitor | | | | |
| Inducer | Erastin, sulforalazine, sorafenib, altretamine, RSL3, ML162, ML210, SAS, laperosine, DPI7, DPI10, FIN56, OIL56, artemisinin, FINO₂ | Ps3, Bax and other Bcl-2 family proteins, Caspase family, endoplasmic reticulum pathway, death receptor | Mostly anti-inflammatory | Mostly pro-inflammatory |
| Inhibitor | Deferoxamine, deferiprone, vitamin E, ferrostatin-1, Liproxstatin-1, DHO, SRS, CA-1, cycloheximide | Ca^{2+}\text-\text{Mg}^{2+}, TGF-β, glucocorticoid, FASL | Rapamycin, lithium, sodium, brefeldin A, thapsigargin, tunicamycin valproate, carbamazepine, xestospongin B/C, C2-ceramide | Sorafenib, artesunate, shikonin, resibufogenin, 5-FU, SM-164 |
| | | | | |
| | | | Necrostatin-1, Necrostatin-2, NSA, Kongensin- A | Necrosulfonamide, VX-765, Z-VAD-FMK, Q-VD-Opz |

*TABLE 1* | The main features of ferroptosis, apoptosis, autophagy, necroptosis, and pyroptosis.
The occurrence of ferroptosis depends on the intracellular iron deposition caused by the disorder of iron metabolism. The body iron intake takes place by tissue macrophage-dependent aging red blood cells engulfing and duodenal enterocytes-mediated diet absorption into the bloodstream. Cellular iron absorption involves the following pathways: transferrin-bound iron pathway, non-transferrin bound iron pathway, SCARAS/TIR1-dependent endocytosis, and hemoglobin-dependent pathway. Intracellular Fe$^{2+}$ formed LIP, stored in FTL and FTH in the cytosol, or as Fe–S in the mitochondrial respiratory chain. IRP/IRE regulates iron homeostasis by regulating the transcription of iron metabolism genes. When cellular iron metabolism is disordered, accumulated intracellular Fe$^{2+}$ undergo Fenton’s reaction with H$_2$O$_2$ to generate OH$^-$, OH$^-$ and other ROS attack the PUFAs on the membrane surface to cause membrane peroxidation and release oxidative toxic substances such as 4-HNE and MDA. Consequently, membrane structure, proteins, and genetic materials are damaged, which affects organelles’ functions and cell homeostasis, causing ferroptosis at last. 4-HNE, 4-hydroxynonenal; ACSL4, long-chain-fatty-acid-CoA ligase 4; DMT1, divalent metal transporters 1; FPN, ferroportin; Fe–S, iron-sulfur clusters; FTH, ferritin heavy chain; FTL, ferritin light chain; HO-1, heme oxygenase 1; IRP/IRE, iron-regulatory protein/iron-responsive element; LIP, labile iron pool; LPCAT3, lysophosphatidylcholine acyltransferase 3; LOX, lipooxygenase; MDA, malondialdehyde; PUFAs, polyunsaturated fatty acids; PE-AA, phosphatidylethanolamines-arachidonoyl; PE-AA-OOH, hydroperoxides of phosphatidylethanolamines-arachidonoyl; PE-ADA, phosphatidylethanolamines-adrenoyl; PE-ADA-OOH, hydroperoxides of phosphatidylethanolamines-adrenoyl; ROS, reactive oxygen species; SCARAS, scavenger receptor class A member 5; TIR1, transferrin receptor 1; ZIP8, Zrt/Zip-related protein 8; ZIP14, Zrt/Zip-related protein 14.

The process of ferroptosis in Neurodegenerative Diseases is shown in the diagram. The body absorbs iron through different pathways: transferrin-bound iron pathway, non-transferrin bound iron pathway, SCARAS/TIR1-dependent endocytosis, and hemoglobin-dependent pathway. Intracellular Fe$^{2+}$ forms LIP, which is stored in FTL and FTH in the cytosol, or as Fe–S in the mitochondrial respiratory chain. IRP/IRE regulates iron homeostasis by regulating the transcription of iron metabolism genes. When cellular iron metabolism is disordered, accumulated intracellular Fe$^{2+}$ undergoes Fenton’s reaction with H$_2$O$_2$ to generate OH$^-$, OH$^-$ and other ROS attack the PUFAs on the membrane surface to cause membrane peroxidation and release oxidative toxic substances such as 4-HNE and MDA. Consequently, membrane structure, proteins, and genetic materials are damaged, which affects organelles’ functions and cell homeostasis, causing ferroptosis at last. 4-HNE, 4-hydroxynonenal; ACSL4, long-chain-fatty-acid-CoA ligase 4; DMT1, divalent metal transporters 1; FPN, ferroportin; Fe–S, iron-sulfur clusters; FTH, ferritin heavy chain; FTL, ferritin light chain; HO-1, heme oxygenase 1; IRP/IRE, iron-regulatory protein/iron-responsive element; LIP, labile iron pool; LPCAT3, lysophosphatidylcholine acyltransferase 3; LOX, lipooxygenase; MDA, malondialdehyde; PUFAs, polyunsaturated fatty acids; PE-AA, phosphatidylethanolamines-arachidonoyl; PE-AA-OOH, hydroperoxides of phosphatidylethanolamines-arachidonoyl; PE-ADA, phosphatidylethanolamines-adrenoyl; PE-ADA-OOH, hydroperoxides of phosphatidylethanolamines-adrenoyl; ROS, reactive oxygen species; SCARAS, scavenger receptor class A member 5; TIR1, transferrin receptor 1; ZIP8, Zrt/Zip-related protein 8; ZIP14, Zrt/Zip-related protein 14.
FIGURE 2  | The regulation of ferroptosis. Multiple pathways inhibit ferroptosis by resisting oxidative distress and inhibiting lipid peroxidation, including systemX\textsubscript{C}/GSH/GPX4 pathway, FSP1/CoQ10 pathway, GCCH1/DHFR/BH4 pathway, DHODH/CoQ pathway, and p62/Keap1/Nrf2 pathway. (1) systemX\textsubscript{C}/GSH/GPX4 pathway: systemX\textsubscript{C}, consisting of SLC7A11 and SLC3A2, is capable to exchange glutamate and cystine equally. Cystine is obtained from methionine through the Sulfur-transfer pathway and then converted to cysteine intracellularly to generate GSH. Selenoprotein GPX4 detects GSH, leading to the reduction of lipid hydroperoxides to lipid alcohols and the simultaneous oxidization of two GSH into oxidized GSSG. IPP, produced by the MVA pathway, transfers isopentyl groups to isopentyl transferases-catalyzed Sec-tRNA precursors which mediate the maturation of Sec-tRNAs responsible for Sec insertion into GPX4. (2) FSP1/CoQ10 pathway: FSP1 converts CoQ10 to CoQ10H2 using NAD(P)H, which quenches lipid free radicals generated by lipid peroxidation. Membrane-associated protein complex ESCRT-III regulates membrane regeneration through membrane germination and cleavage. FSP1 transported in the plasma membrane can resist ferroptosis by enrolling ESCRT-III to activate the membrane restore mechanism. (3) GCCH1/DHFR/BH4 pathway: BH4 is a potent free radical scavenger that exerts antioxidant effects in cells. The interconversion between the oxidation and reduction forms of BH4 is controlled by two enzymes, GCCH1 and DHFR. The synthesis of BH4 by GCCH1 expression selectively prevents PUFA-PL depletion-induced membrane lipid remodeling. DHFR is an essential enzyme for BH4 regeneration, and its inhibition may synergize with GPX4 inhibitors to induce ferroptosis. BH4 can also quench ROS by promoting the synthesis of CoQ10. (4) DHODH/CoQ pathway: DHODH is an enzyme present on the inner surface of mitochondria that catalyzes substrates DHO to produce OA. DHODH cooperates with mitochondrial GPX4 to regulate mitochondrial ferroptosis by reducing CoQ to CoQH\textsubscript{2} on the mitochondrial intima independently of the cytoplasmic GPX4 or FSP1 pathways. (5) p62/Keap1/Nrf2 pathway: Under oxidative distress conditions, p62 prevents the degradation of Nrf2 in the Keap1-CUL3-RBX1 E3 ubiquitin ligase complex. Nrf2 undergoes nuclear translocation and binds to ARE to initiate transcription of multiple cytoprotective genes against ferroptosis. Nrf2-mediated protein-DNA interaction regulates the expression of FTH, FTL, FPX, NTF, HO-1, and so on for controlling cellular iron metabolism, promoting SLC7A11 expression, and increasing the production of NADPH, GSH, and CoQ10 to enhance the antioxidant capacity of cells. α-TOH, α-tocopherol; ARE, antioxidant response element; BH\textsubscript{2}, dihydrobiopterin; BH4, tetrahydrobiopterin; CoQ, coenzyme Q; CoQ10, coenzyme Q; CoQH\textsubscript{2}, reduced coenzyme Q; CUL3, cullin 3; DHFR, dihydrofolate reductase; DHO, dihydroorotate acid; DHODH, dihydroorotate dehydrogenase; ESCRT-III, endosome sorting complex; FTH, ferritin heavy chain; FTL, ferritin light chain; FSP1, ferroptosis suppressor protein 1; GCCH1, GTP cyclohydrolase-1; GPX4, glutathione peroxidase 4; GSH, glutathione; GSSG, oxidized glutathione; GTP, guanosine triphosphate; HO-1, heme oxygenase-1; IPP, isopentenyl transferase; IPX, isopentenyl pyrophosphate; Keap1, KELCH-ECH-associated protein 1; MVA pathway, mevalonate Regulation pathway; NADH, reduced nicotinamide adenine dinucleotide; NADPH, oxidized nicotinamide adenine dinucleotide (phosphate); NAD(P)H, reduced nicotinamide adenine dinucleotide (phosphate); Nrf2, nuclear factor 2-related erythroid factor 2; OA, orotate; RBX1, RING-box protein 1; Sec, selenocysteine; SLC3A2, solute carrier family 3 member 2; SLC7A11, solute carrier family 7 member 11; TFRC, transferrin receptor.
the electron transport chain (Paul et al., 2017). Furthermore, Fe–S clusters are important cofactors to ensure the normal functioning of key enzymes in DNA metabolism, such as DNA helicases and DNA polymerases (Puig et al., 2017). Mitochondrial ferritin (FtMt) is a specific protein that stores iron in mitochondria, and its main function is to participate in the formation of mitochondrial iron pools to maintain iron homeostasis (Campanella et al., 2009).

Iron Regulation
Iron regulatory proteins (IRPs), including IRP1 and IRP2, play important roles in maintaining cellular iron homeostasis. IRP regulates iron metabolizing genes transcripts by binding to the iron response element (IRE) in 3′-untranslated region (UTR) or 5′-UTR (Gao et al., 2019). When intracellular iron is low, Fe–S occupying the active site of the IRP is released, allowing DMT1 and TfR gene transcripts to bind to IRE and increase their translation, while IRPs bind to 5′-UTR-bound FPN gene transcripts inhibits its translation, thereby reducing cellular iron excretion and increasing absorption to promote intracellular free iron growth (Wei et al., 2020). The accumulated Fe^{2+} undergoes Fenton’s reaction with H_2O_2 to produce a large amount of OH , one of the ROS with strong oxidative capability, which leads to the destruction of the cell membrane by oxidative damage. Regulation of iron homeostasis prevents intracellular iron accumulation by regulating iron absorption, utilization, storage, and excretion, which is one of the most important ways to prevent ferroptosis. Iron chelators, such as deferoxamine (DFO), deferoxiprone (DFP), and ciclopirox olamine, can suppress ferroptosis by profound depletion of intracellular iron (Eberhard et al., 2009; Nikseresht et al., 2019). Zinc protoporphyrin IX (ZnPPIX) is a specific HO-1 inhibitor that reduces Fe^{2+} produced by intracellular heme breakdown and inhibits erastin-induced ferroptosis (Gammella et al., 2015). Decreased Recombinant iron responsive element binding protein 2 (IREB2) expression can also inhibit ferroptosis by improving the intracellular storage capacity of ferritin (Kwon et al., 2015).

Lipid Peroxidation
Lipid metabolism is essential for ferroptosis, and lipid peroxidation induced by ROS represents the state of oxidative stress, which is a triggering factor of ferroptosis. Polysaturated fatty acids (PUFAs) with labile bis-allylic hydrogen atoms are especially susceptible to ROS damage (Yang et al., 2016). PUFAs and polysaturated acyl-tailed phospholipids (PUFA-PL) are necessary for the normal execution of ferroptosis, which can generate ROS and lipid peroxides such as malondialdehyde (MDA), 4-hydroxynonenal (4-HNE), and lipid hydroperoxides (LOOHs) through enzymatic catalysis or autooxidation (Dixon and Stockwell, 2014; Stockwell et al., 2017). In cells under ferroptotic stress, Fenton’s reaction-mediated OH- production and lipid peroxidation generate toxic products that damage cellular proteins and nucleic acids, resulting in cellular dysfunction and even death.

The key phospholipids involved in ferroptosis are phosphatidylethanolamines (PE), including phosphatidylethanolamines-arachidonoyl (PE-AA) and phosphatidylethanolamines-adenoyl (PE-ADA) (Kagan et al., 2017). PE-AA and PE-ADA are important substrates for lipid peroxidation. Long-chain-fatty-acid-CoA 4 (ACSL4) esterifies coenzyme A (CoA) and catalyzes AA to intermediate AA-CoA (Doll et al., 2017). In the endoplasmic reticulum, lysophosphatidylcholine acyltransferase 3 (LPCAT3) binds PUFAs to AA-COAs using PE as a substrate, forming a PE-AA-rich membrane microenvironment (Lee et al., 2021). Finally, PE-AA and PE-ADA undergo peroxidation by lipoxygenases (LOXs) to generate PUFAs, which leads to ferroptosis ultimately (Wenzel et al., 2017). LOXs, especially LOX15, are catalysts for highly selective and specific oxidation reactions of PE-AA and PE-ADA (Stoyanovsky et al., 2019). LOX15 forms a PEBP1/LOX15 complex with phosphatidylethanolamine-binding protein 1 (PEBP1), which promotes the peroxidation of PE to PE-AA-hydrogen peroxide (OOH) metabolites (Wenzel et al., 2017). High concentrations of PE-AA-OOH in cell and organelle membranes are also prone to oxidative cleavage of loosely bound iron, and electrophilic ions attack functional proteins, resulting in impaired cellular integrity and function (Anthonymuthu et al., 2021).

Lipid peroxidation inhibitors represented by the Vitamin E family can effectively inhibit the activities of LOX, ACSL4, and LPCAT3, and prevent ferroptosis by reducing the accumulation of executioners (Mabaliirajan et al., 2009; Zhang et al., 2022). Furthermore, activated protein kinase (AMPK) may regulate a mitochondrial-independent mechanism of acetyl-CoA carboxylase under energy stress by reducing PUFA biosynthesis and inhibiting ferroptosis (Lee et al., 2020).

SystemX^-/GSH/GPX4 Pathway
Among anti-ferroptosis defense pathways, the aforementioned iron metabolism and oxidative distress, there are anti-ferroptosis pathways that inhibit ferroptosis by inhibiting lipid peroxidation, including systemX^-/GSH/GPX4 pathway, GCH1/DHFR/BH4 pathway, FSP1/CoQ10 pathway, DHODH/CoQ pathway, and p62/Keap1/Nrf2 pathway (Figure 2). When cellular anti-ferroptosis defense pathways are interrupted, free lipid radicals are generated in the presence of free iron. It makes polysaturated fatty acids susceptible to lipid peroxidation, leading to irreversible oxidative distress damage to biofilms or genetic material and resulting in cell death eventually (Guichardant et al., 2011; Hadian and Stockwell, 2020).

SystemX^-/GSH/GPX4 Pathway
Among anti-ferroptosis defense pathways, the systemX^-/GSH/GPX4 pathway related to amino acid metabolism is widely studied. SystemX^- consists of two subunits, solute carrier family 7 member 11 (SLC7A11) and solute carrier family 3 member 2 (SLC3A2). SystemX^- is widely distributed in the phospholipid bilayer and play an central role in the exchange of glutamate and cystine. After entering the cell, cystine converts to cysteine, which can also be obtained from methionine through the Sulfur-transfer pathway (Zheng and Conrad, 2020). Afterward, glutathione (GSH), an important free radical scavenger in organisms, is generated from...
cysteine, glutamate, and glycine under the action of glutathione synthase (Lin et al., 2020; Chen L. et al., 2021). Cysteine provides sulphydryl, an active group with antioxidant effect for GSH. Glutathione peroxidase 4 (GPX4) is a selenoprotein whose main cofactor is GSH, which reduces lipid hydroperoxides to lipid alcohols and simultaneously oxidizes two GSH to oxidized glutathione (GSSG) (Seibt et al., 2019).

The systemX\textsuperscript{−}/GSH/GPX4 pathway plays an important role in the downregulation of ferroptosis. Increasing extracellular glutamate concentration or decreasing cystine uptake inhibits systemX\textsuperscript{−} to promote ferroptosis (Hambricht et al., 2017). The classic ferroptosis inducers such as erastin and sulfadiazine block the absorption of GSH by inhibiting the systemX\textsuperscript{−} (Dixon and Stockwell, 2014). p53 is a tumor suppressor protein that inhibits cystine cellular uptake by decreasing the expression of SLC7A11, resulting in reduced GPX4 activity and elevated susceptibility to ferroptosis (Jiang et al., 2015). Glutaminase 2 (GLS2), an enzyme necessary for glutamine hydrolysis is considered as an important target protein of p53. The GLS2 inhibitor compound 968 and artificial oocyte activation (AOA) inhibit erastin-induced ferroptosis (Gao et al., 2015; Jennis et al., 2016).

GPX4 is the first major regulator of ferroptosis. The compounds including RSL3, DP17, and DP110 can inhibit GPX4 directly, resulting in the accumulation of lipid peroxides and ROS for ferroptosis (Yang et al., 2014; Yang and Stockwell, 2016). The activity of GPX4 is also associated with the Mevalonate Regulation pathway (MVA pathway) (Dixon et al., 2014). Selenocysteine (Sec) is the active central amino acid of GPX4, and the Sec-tRNA is responsible for embedding Sec into GPX4. Isopentenyl pyrophosphate (IPP) produced by the MVA pathway transfers the isopentyl group to the Sec-tRNA precursor catalyzed by isopentenyl transferase, mediating the maturation of that specific tRNA (Writh et al., 2014). The use of statins downregulates the MVA pathway, reduces IPP production, and disrupts Sec-tRNA maturation, resulting in deficiency of selenoprotein and cellular antioxidant capacity, ultimately, promoting ferroptosis (Watanabe et al., 2021).

**GCH1/DHFR/BH4 Pathway**

The GCH1/DHFR/BH4 pathway, discovered by Kraft and Soula in 2018, is a unique anti-ferroptosis mechanism independent of GPX4. Tetrahydrobipterin (BH4) is a potent free radical scavenger that exerts antioxidant effects in cells through two enzymes, GTP cyclohydrolase-1 (GCH1) and dihydrofolate reductase (DHFR). Two enzymes are responsible for the interconversion between the oxidation and reduction forms of BH4. The synthesis of BH4 by GCH1 expression selectively prevents PUFA-PL depletion-induced membrane lipid remodeling (Kraft et al., 2020). DHFR is an essential enzyme for BH4 regeneration, and its inhibition may synergize with GPX4 inhibitors to induce ferroptosis (Soula et al., 2020). In addition, BH4 can also quench ROS by promoting the synthesis of Coenzyme Q10 (CoQ10) (Kraft et al., 2020). CoQ10/CoQ10H\textsubscript{2} is an antioxidant that scavenges free radicals on cell membranes and maintains the fluidity and integrity of cell membranes.

**FSP1/CoQ10 Pathway**

The FSP1/CoQ10 pathway was discovered by Bersuker et al. (2019) and Doll et al. (2019). Ferroptosis suppressor protein 1 (FSP1) converts CoQ10 to CoQ10H\textsubscript{2} using NAD(P)H, which quenches lipid free radicals generated by lipid peroxidation. FSP1 inhibits lipid peroxidation and ferroptosis independently of systemX\textsuperscript{−}/GSH/GPX4 pathway and still has a protective effect after GPX4 knockout (Stockwell, 2019). Homologous murine double minute 2 homolog (MDM2) and murine double minute X (MDMX) proteins are the two negative regulators of p53. Inhibition of MDM2 or MDMX increases the levels of FSP1 and CoQ10, leading to inhibition of ferroptosis in a p53-independent manner (Venkatesh et al., 2020). In addition, the endosomal sorting complex required for transport III (ESCRT-III) is a membrane-associated protein complex that regulates membrane regeneration through membrane germination and cleavage. FSP1 transported in the plasma membrane can resist ferroptosis by enrolling ESCRT-III to activate the membrane restore mechanism (Dai et al., 2020b). Activation of ferroptosis inducers such as soraferib by regulating FSP1-ESCRT-III has been emerged as a novel anti-tumor strategy (Dai et al., 2020a).

**DHODH/CoQ Pathway**

In 2021, Mao et al. discovered a mitochondrial anti-ferroptosis defense mechanism mediated by dihydroorotate dehydrogenase (DHODH), which inhibits ferroptosis by reducing CoQ to CoOH\textsubscript{2} on the IMM (Mao et al., 2021). DHODH is an enzyme present on the inner surface of mitochondria, whose substrates are dihydroorotate acid (DHO) and its reaction product is orotate (OA). DHO and OA have opposite effects on GPX4 inhibitor-induced ferroptosis. DHO exerts a protective role, while OA just the reverse. DHODH loss-of-function leads to extensive lipid peroxidation in mitochondria and ferroptosis in cancer cells with low GPX4 levels. Taken together, DHODH regulates mitochondrial ferroptosis independently of the cytoplasmic GPX4 or FSP1 pathways, while cooperates with mitochondrial GPX4.

**p62/Keap1/Nrf2 Pathway**

Nuclear factor 2-related erythroid factor 2 (Nrf2) is a major antioxidant element against oxidative distress in cells and a key transcriptional regulator of ferroptosis. Nrf2 is normally degraded by specific proteasome ubiquitination mediated by the Keap1-CUL3-RBX1 E3 ubiquitin ligase complex. The double-glycine repeat (DGR) domains of the Keap1 homodimer bind with the DLG and ETGE domains in Nrf2 (Bellezza et al., 2018). p62 directly interacts with Keap1, which inhibits the activity of Keap1 to bind Nrf2 (Komatsu et al., 2010). The release of DLG motif in Nrf2 from Keap1 blocks Nrf2 ubiquitination and degradation, therefore increasing the antioxidant capacity of cells (Bellezza et al., 2018). Activation of the p62/Keap1 pathway increases the antioxidant capacity of cells and inhibits the occurrence of ferroptosis (Sun et al., 2016). When stimulated by oxidative distress, Nrf2 undergoes nuclear translocation and binds to antioxidant response element (ARE) to initiate transcription of a variety of cytoprotective genes (Matsumaru and Motohashi, 2021). For example, Nrf2 regulates the expression...
of FTH and FTL for iron storage, FPN and TFRC for iron transport, and HO-1 for intracellular iron production, therefore controlling cellular iron metabolism (Zhao et al., 2021). Nrfe2 can promote the expression of SLC7A11, glutathione synthase (GSS), and glucose-6-phosphate dehydrogenase (G6PD), which increases the production of NADPH, GSH, and CoQ10 to enhance the antioxidant capacity of cells (Shin et al., 2017; Carpi-Santos and Calaza, 2018; Dodson et al., 2019; Zheng and Conrad, 2020). Besides, Nrfe2 regulates oxidative distress-induced lipid accumulation by regulating autophagy proteins including ATG5 and lipogenesis proteins such as Sterol regulatory element binding proteins (SREBPs) (Bai et al., 2019; Sun et al., 2020).

**EMERGING LINKS OF FERROPTOSIS TO NEURODEGENERATIVE DISEASES**

NDDs are a group of diseases characterized by protein intra- and extracellular deposition and gradual loss of a specific population of neurons, with progressive motor and cognitive decline (Baloni et al., 2021). There is growing evidence that ferroptosis and NDDs are inextricably linked. Currently, studies on ferroptosis in NDDs mainly focus on AD, PD, HD, and ALS. Although different NDDs have different mechanisms in disease evolution, ferroptosis is proven to be involved in all of them and characterized by altered brain iron homeostasis, dysregulation of antioxidant system and oxidative damage (Table 2).

**Ferroptosis and Alzheimer’s Disease**

Alzheimer’s disease is the most common NDD manifested as progressive decline in cognitive function, including impairment of multiple cognitive domains such as memory, executive function, and language (Tiwari et al., 2019). The typical pathologic features of AD are the presence of senile plaques (SP) formed by extracellular amyloid (Aβ) deposition and intracellular neurofibrillary tangles (NFTs) formed by hyperphosphorylated tau protein, ultimately leading to neuronal dysfunction and synapse loss (Lane et al., 2018). Multiple theories have been proposed regarding the mechanism of AD progression, which include neuroinflammation, Aβ overproduction/aggregation, tau hyperphosphorylation, neurotranmitter disorders, and mitochondrial dysfunction (Xia et al., 2021). Aging, genetic factors (e.g., altered APOE gene), environmental factors, and vascular diseases are considered as risk factors for AD (Tang et al., 2022). However, this does not appear to be fully sufficient to explain the pathogenesis of AD.

In recent years, the theory of the metal homeostasis mechanism represented by ferroptosis has been supported by increasing amounts of evidence (Hambright et al., 2017; Zhang et al., 2021). Human brain tissue from AD patients exhibits abnormal iron metabolism and glutamate levels, damaged systemXc−, and induced apparent lipid peroxidation (Hambright et al., 2017; Ayton et al., 2020). Iron deposition occurs in the hippocampus and the inferior temporal cortex of AD patients, and is strongly associated with loss of memory and cognitive decline (Ayton et al., 2020; You et al., 2021). Quantification of iron deposition using susceptibility-weighted imaging (SWI) indicates iron deposition in eight brain regions including prefrontal, parietal, temporal, amygdala, putamen, globus pallidus, cingulate cortex, and caudate nucleus in advanced AD patients (Ashraf et al., 2020). Being the only exit for iron excretion through cells, FPN1 has been found to be downregulated in the brains of AD patients and AD animal models to induce intracellular iron accumulation (Raha et al., 2013; Bao et al., 2021). Furthermore, they found that differentially expressed genes (DEGs) in ferroptosis were highly enriched in AD-related gene concentrations through Gene Set Enrichment Analysis (GSEA), which was consistent with the conclusion of Majerniková et al. (2021) after analysis of four datasets of AD DEGs. These literatures prompt a strong association of ferroptosis with the pathogenesis of AD.

Abnormal iron metabolism can result in post-translational production of inappropriately modified Aβ, leading to an abnormal increase in Aβ oligomers (Derry et al., 2020). Iron deposition promotes the expression and abnormal degradation of amyloid precursor protein (APP) through the intracellular IRE/IRP regulatory system, a control element for cellular iron homeostasis (Altamura and Muckenthaler, 2009; McIntosh et al., 2019; Derry et al., 2020). Abnormal elevation of divalent iron in AD brain induces tau hyperphosphorylation and aggregation, leading to the formation of NFTs (Wan et al., 2019). Amyloid plaques and NFTs therefore mediate ferroptosis-mediated neuronal death and AD-related cytotoxicity. Microglial activation and neuroinflammation are also typical changes during the pathogenesis of AD. Hippocampal microglia and astrocytes of AD patients contain high levels of ferritin (Zeineh et al., 2015). Iron accumulation induces the phenotype transition of microglia to a pro-inflammatory one and the reprogramming of cellular metabolism that reduces the Aβ clearance capacity of microglia (van Duijn et al., 2017; McIntosh et al., 2019).

Studies of ferroptosis suggest potential biomarkers for early prediction of AD. As mentioned above, abnormal iron metabolism has emerged as an important pathological characteristic. Quantitative susceptibility mapping (QSM) was used to observe the spatial co-localization of brain iron deposition and Aβ plaques in pre-AD patients, which demonstrated Aβ accumulation along with iron deposition (van Bergen et al., 2016b). Therefore, the imaging evidence of iron deposition has been proposed as an important diagnostic index of AD (Tao et al., 2014; Ayton et al., 2020). APOEε4, a risk factor for the development of AD, increases carrier susceptibility by increasing ferritin levels (Ayton et al., 2015). Cerebrospinal fluid (CSF) ferritin levels are positively associated with the risk of cognitive decline in AD patients with APOEε4 genotype, hence researchers also recommend CSF ferritin levels as a biomarker for AD (Ayton et al., 2018; Diouf et al., 2019).

Inspiringly, several studies have shown favorable therapeutic effects of ferroptosis inhibitors on AD animals (Zhang et al., 2018; Komaki et al., 2019; Rao et al., 2020; Farr and Xiong, 2021). The iron chelators DFO and DFP are widely used as specific inhibitors of ferroptosis. Preclinical evidence suggests that iron chelators modulate iron homeostasis, mitigate oxidative distress, improve cognition and behavioral outcomes in AD mice (Rao et al., 2020; Farr and Xiong, 2021). CoQ10 has
TABLE 2 | Pathological changes of NDDs associated with pathological features of ferroptosis.

| Diseases | Ferroptosis-related Pathological Features | Potential pathological outcome | References |
|----------|------------------------------------------|-------------------------------|------------|
| AD       | Abnormal iron metabolism and iron deposition | Accumulation and aggregation of Aβ and Tau proteins | Ayton et al., 2020; Derry et al., 2020 |
|          | Abnormal increase in APP level and tau hyperphosphorylation and aggregation; Microglial activation and neuroinflammation | | Altamura and Muckenthaler, 2009; McIntosh et al., 2019; Derry et al., 2020 |
|          | Neuronal death and NFT deterioration | | Wan et al., 2019 |
| Redox imbalance and oxidative stress | Abnormal increase of Aβ oligomer and neuroinflammation | | Saito et al., 2019 |
| Decreased GPX4 protein levels and elevated lipid peroxidation products | Hippocampal neurodegeneration | | Hambright et al., 2017 |
| PD       | Oxidative distress and lipid peroxidation | Degeneration and loss of dopaminergic neurons | Dias et al., 2013; Hare and Double, 2016; Dionisio et al., 2021 |
|          | Abnormal iron metabolism and lipid peroxidation | α-synuclein aggregation | Angelova et al., 2020; Riederer et al., 2021 |
| Increased iron in SN | Aggregation and dopaminergic neuron death | Wang et al., 2009; Zhu et al., 2017; Zhang Y. et al., 2020 |
| Decreased GPX4 in SN | Dopaminergic neuron axon damage | Bellinger et al., 2011 |
| Decrease FPN expression | Microglia proinflammatory transformation | Zhang et al., 2014 |
| Iron homeostasis and iron deposition | Microglia activation and dopaminergic cell death | Wang Z. L. et al., 2022 |
| Down-regulation of the SLC7A11 gene and decreased SLC7A11 protein level | Neuroinflammation | Vallerga et al., 2020 |
| Elevated lipid peroxidation products and decreased GSH protein level | Increased Lewy bodies | Jenner et al., 1992 |
| DJ-1 gene mutation | Decreased GPX4 and GSH activity | Cao et al., 2020 |
| Decreased GPX4 activity | Mitochondrial dysfunction and oxidative distress damage | Agrawal et al., 2018 |
| Recurrent glutamate abnormalities | HTTP gene variants | Mason et al., 2013 |
| ALS      | GPX4 depletions | Mitochondrial dysfunction | Reddy and Shirendeb, 2012 |
|          | Loss of motor neurons | Evans et al., 2022 |
|          | SOD1 gene mutations | Jeong et al., 2009 |
|          | SOD1 gene mutations | Wang et al., 2021; Peng et al., 2022 |
| MS       | Decreased GSH protein level and systemXc− activity | Microglial activation and neuroinflammation | Hu et al., 2019 |
|          | Glutathione deficiency and lipid peroxidation | Oligodendrocyte loss and demyelination | Jhelum et al., 2020 |

been shown to inhibit ferroptosis in AD mice by inhibiting lipid peroxidation. After pretreatment of AD mice with CoQ10, MDA was decreased and oxidative distress was alleviated significantly, suggesting that CoQ10 exerts neuroprotective effects on Aβ-induced nerve damage (Komaki et al., 2019). The antioxidant alpha-lipoic acid (ALA) significantly inhibited tau-induced iron overload and reduced NFTs formation by enhancing GPX4 expression (Zhang et al., 2018). Similarly, Forsythoside A, the main component of Forsythia suspensa (Thunb.) Vahl, and Ginkgolide B, a terpene lactone derivative of Ginkgo biloba, also exhibited anti-AD properties via inhibiting ferroptosis-mediated neuroinflammation by activating Nrf2/GPX4 axis (Shao et al., 2021; Wang C. et al., 2022). Vitamin E can neutralize peroxidative free radicals, terminate lipid peroxidation, and reduce the risk of cognitive decline following high vitamin E supplementation in AD patients (Basambombo et al., 2017). CMS121, a lipoxygenase inhibitor, reduces the relative levels of fatty acids and PUFAs in AD mice and improves cognitive dysfunction by inhibiting lipid peroxidation (Everett et al., 2020). However, although ferroptosis inhibitors have exhibited promising therapeutic effects in AD animal models, there are still in lack of clinical evidence to support these findings, which is urgently needed to confirm ferroptosis as an important therapeutic target for AD.

**Ferroptosis and Parkinson's Disease**

Parkinson's disease is the second most common NDD. Clinical symptoms of PD include motor symptoms (e.g., resting tremor, muscle rigidity, bradykinesia, and postural disorders) and non-motor symptoms (e.g., sleep disorders, depression, and cognitive dysfunction) (Parkinson, 2002). The most outstanding character...
of PD is the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), resulting in striatal dopamine depletion, neuromelanin loss, and the appearance of α-synuclein (α-syn)-rich Lewy bodies in neurons (Hayes, 2019).

Numerous studies have implicated the increase of ferroptosis-associated oxidative distress and lipid peroxidative damage as important features of PD pathophysiology (Dionisio et al., 2021; Mahoney-Sánchez et al., 2021; Riederer et al., 2021). The SNpc and brainstem of PD patients have obvious iron deposition, and the iron concentration in the substantia nigra (SN) is related to the severity of the disease (Wieler et al., 2015). Animal studies also identified SN as the most susceptible brain region for iron accumulation during aging (Jia et al., 2018). The magnitude of elevated iron levels significantly correlated with the magnitude of α-syn aggregation, iron deposition, and dopaminergic (DA) neuron death in early-stage PD patients and PD animal models (Wang et al., 2009; Zhu et al., 2017; Zhang Y. et al., 2020). The studies of possible mechanisms revealed that iron combines with DA to form a potent oxide, which simultaneously produces dopamine quinone and 6-hydroxydopamine (6-OHDA). 6-OHDA can release iron from ferritin while exerting a new round of oxidative distress and neurotoxicity damage (Dias et al., 2013; Hare and Double, 2016). Meanwhile, high levels of iron in dopaminergic neurons exacerbate oxidative distress due to Fenton’s reaction (Dias et al., 2013; Hare and Double, 2016). Furthermore, total GPX4 levels are significantly reduced in the substantia nigra of PD patients (Bellinger et al., 2011). SLC7A11 was also hypermethylated in PD, severely affecting systemXc− activity (Vallerga et al., 2020). Hence, the abnormal activities of systemXc−/GSH/GPX4 pathway in the SN have been proposed as an early event in PD pathogenesis (Jenner et al., 1992). In recent years, α-syn oligomers have been reported to induce ferroptosis by interacting with cell membranes and promoting lipid peroxidation (Angelova et al., 2020). In addition, an in vitro PD model further showed that FPN1 activity in SN microglia is inhibited and iron secretion is blocked, causing pro-inflammatory transformation (Zhang et al., 2014). Activation of glial cells and iron homeostasis-induced iron deposition form a “partners in crime” that alter cellular metabolic state, exacerbate oxidative distress, and induce ferroptosis on DA neurons (Wang Z. L. et al., 2022).

Due to the importance of ferroptosis in the pathogenesis of PD, iron metabolism and systemXc−/GSH/GPX4 pathway have been considered as promising therapeutic targets of PD. Iron chelators such as DFO have been shown to reduce oxidative distress damage and increase dopaminergic neuron activity, thereby improving motor symptoms (Do Van et al., 2016). Human brain imaging studies have shown that DFP decreases brain iron levels, alters cerebrospinal fluid ferritin, and mitigates dyskinesia (Martin-Bastida et al., 2017). Similarly, both the blockage of ferritin degradation by ferritinophagy inhibitors chloroquine and bafilomycin A1 and the application of an iron-free form of ferritin, apoferritin, have been reported to chelate excess iron to protect DA neurons against PD (Tian et al., 2020; Song et al., 2021). Moreover, NADPH oxidase inhibitor apocynin was also found to inhibit iron accumulation and lipid peroxidation, therefore ameliorating dopaminergic neurodegeneration and motor function abnormality in PD mice (Hou et al., 2019). Early-onset autosomal recessive PD is often accompanied by mutations in the DJ-1 gene. Using the antioxidant enzyme DJ-1 as a ferroptosis inhibitor can stabilize the sulfur transmission pathway, ensure the activity of GPX4 and GSH, and reduce susceptibility to ferroptosis (Cao et al., 2020). Elimination of oxidative distress is a novel therapeutic strategy. Diacetyl bis (4-methyl-3-thiosemicarbazonoato) copperII [CuII (atsm)], a hypoxia-sensitive positron emission tomography imaging agent, has the greatest potential in the treatment of various NDDs (Zilka et al., 2021). In vivo and in vitro PD model experiments confirmed that CuII (atsm)-mediated activation of Nrf2-related antioxidant enzymes improved motor and cognitive functions, protected SN cells against lipid peroxidation, and improved DA metabolism (Hun et al., 2012; Southon et al., 2020). Encouragingly, CuII (atsm) has achieved preliminary positive treatment outcomes in a phase I clinical trial in PD patients (NCT03204929).

Ferroptosis and Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis is a degenerative motor neuron disease featured by the progressive loss of motor neurons in the spinal cord, brainstem, and motor cortex, resulting in progressive muscle weakness and loss of respiratory function, leading to premature death (Vahsen et al., 2021). ALS is currently thought to be associated with gene mutation (e.g., SOD1 gene mutation), glutamate excitotoxicity, oxidative distress, immune disorders, mitochondrial dysfunction, and reduced axonal transport, but the exact etiology and pathogenesis remain unclear (Brown and Al-Chalabi, 2017; Hemerková and Vališ, 2021).

Ferroptosis has been implicated in the pathological process of ALS. Iron deposits were observed in the spinal cord, motor cortex, basal ganglia, and thalamus in ALS patients by MRI. Abnormally elevated iron levels were also found in the cerebrospinal fluid (Ignjatović et al., 2012; Kwan et al., 2012). The development of ALS is associated with increased oxidative damage caused by mutations in the free radical scavenging protein superoxide dismutase 1 (SOD1) gene. Deregulated ferritin and blocked intracellular iron efflux in neurons have been found in SOD1 transgenic mice, thereby increasing intracellular iron load (Jeong et al., 2009). SOD1 mutation also activates hypochlorous acid (HOCl)-myeloperoxidase (MPO) pathway, accelerating ROS accumulation and inhibiting GPX4 expression and thus leading to irreversible lipid peroxidation (Peng et al., 2022). Similar to SOD1 transgenic mice, other ALS animal models including TDP-43 and C9orf72 transgenic mice show GPX4 depletion and dysregulation of glutathione synthesis and iron-binding proteins as well (Wang et al., 2021). The in vivo studies have been corroborated by in vitro ALS model. hTGBK1-c.978T > A mutation induces severe cell ferroptosis, which significantly inhibits the proliferation of NSC-34 cells (Zhang P. et al., 2020).

The involvement of ferroptosis in the progression of ALS has been widely examined. Gpx4 neuron inducible knockout (Gpx4NIKO) mice display ALS-like paralytic symptoms
and spinal motor neuron death (Evans et al., 2022). The overexpression of GPX4 in ALS mouse models exhibits reduced systemic cytotoxicity of SOD1, late delayed disease-onset, improved motor function, and longer survival, which are associated with faster recovery from spinal motor neuron injury and repressed lipid peroxidation (Chen X. et al., 2021). Recent studies have further shown that human iPS cell-derived motor neuron (hiMN) death is associated with GPX4, which can be rescued by iron chelators and lipid peroxidase inhibitors, suggesting that iron toxicity has an important pathophysiological role in hiMN death (Matsuo et al., 2021). These evidences indicate a great contribution of ferroptosis to motor neuron degeneration in ALS.

The important role of ferroptosis in ALS also provides novel insights into the treatment and prognosis of ALS. The use of high-affinity, lipophilic iron chelator SIH results in improved spinal motor neuron survival and restored motor function (Jeong et al., 2009). Similarly, the treatment of conservative ferroptosis inhibitors such as Edaravone and DFP also exhibits promising neuroprotective effects on ALS (Devos et al., 2020). Edaravone is a clinically approved free radical scavenger for the treatment of ALS that largely inhibits ferroptosis in cystine deficiency and systemXc−/GPX4 inhibition, preventing devastating motor neuron damage (Spasić et al., 2020; Al-Chalabi et al., 2021). In a single-center pilot clinical study, patients treated with DFP (30 mg/kg/day) for 3 months showed improved ALS functional scores, mitigated oxidative distress, and reduced levels of cerebral iron and neurofilament light chain in the CSF. This study is the first to demonstrate the feasibility of iron chelators in the clinical management of ALS (Moreau et al., 2018). Furthermore, higher levels of baseline neurofilament light chain, 4-HNE, 8-oxo-2′-desoxyguanosine, and ferritin have been found to be independently associated with greater ALSFRS-r decline, suggesting the predictive value of these ferroptosis-related biomarkers for ALS diagnosis and prognosis (Devos et al., 2019).

**Ferroptosis and Huntington’s Disease**

Huntington’s disease is an autosomal dominant NDD, which is featured by involuntary random movements, cognitive decline and personality changes (Wyant et al., 2017). In the first exon of the HTTP gene, the CAG triplet expands and repeats, the HTTP variants predispose to abnormal conformation of the HD protein, severing high levels of toxic molecules in the brain, resulting in disruption of antioxidant gene transcription, and disruption of cellular protein damage processing systems leads to neuronal degeneration and cell death due to oxidative distress (Ross and Tabrizi, 2011).

Neuronal death in HD shows the typical symptoms of ferroptosis, namely recurrent glutamate abnormalities, increased lipid peroxidation, decreased GSH, and persistent iron accumulation (Klepac et al., 2007; Agrawal et al., 2018; Mi et al., 2019). QSM revealed elevated iron levels in the caudate nucleus and putamen of the forebrain in HD patients (van Bergen et al., 2016a). Typical phenotypes of ferroptosis with reduced GSH levels and GPX4 activity, massive iron accumulation in neurons and lipid peroxidation were found in HD animal models (Reddy and Shirende, 2012; Mason et al., 2013). *In vitro* models also demonstrated the importance of ferroptosis in HD pathogenesis as ferrostatin-1 effectively prevented ferroptosis in HTT exon-overexpressing cells (Skouta et al., 2014).

Inhibition of ferroptosis is beneficial in impeding the pathological progression of HD. Mounting studies have demonstrated that CoQ10 supplementation for HD patients can improve mitochondrial function and alleviate membrane lipid peroxidation caused by oxidative distress (Andrich et al., 2004). CoQ10 supplementation in R6/2HD mice had neuroprotective effects on motor performance and prolonged survival of HD mice, by alleviating the reduced glutathione production, lipid peroxidation and oxidative DNA damage (Yang et al., 2009). Besides, targeting iron and activating Nrf2-mediated pathway can be potential therapeutic strategies for HD (Mi et al., 2019). Both the activation of Nrf2 by the cyanoenone triterpenoids CDDO-ethyl amide/CDDO-trifluoroethyl amide and the disruption of Keap1-Nrf2 interaction by KEAP1-modifying small molecule MIND4-17 significantly enhance antioxidant functions of brain cells and ameliorate the behavioral phenotype in HD mouse (Stack et al., 2010; Quinti et al., 2017). Therefore, the above evidences demonstrated a key role of ferroptosis in the pathogenesis of HD, suggesting ferroptosis as an important target for treating and/or preventing HD.

**Ferroptosis and Multiple Sclerosis**

Multiple sclerosis is a chronic autoimmune disease of the human central nervous system (CNS), characterized by neuroinflammation, demyelination, oligodendrocyte loss, and neurodegeneration (Lucchinetti et al., 1996). Recent progress in understanding the pathogenesis of MS suggests major roles for microglia in the disease, in which microglia alter their transcriptional profile and activate into profuse inflammatory phenotypes (Voet et al., 2019).

Pioneer studies were carried out to unveil the association of ferroptosis with microglia-driven neuroinflammation and MS. Hu et al. (2019) reported reduced GPX4 expression levels in the gray matter of MS patients and in the spinal cord of experimental autoimmune encephalomyelitis (EAE) mice, a classic MS mouse model. Further studies demonstrated that ferroptosis mediated rapid loss of oligodendrocytes and demyelination induced by cuprizone, a widely used copper chelator to induce MS-like pathological phenotype (Jhelum et al., 2020). The inflammatory responses of microglia in *vitro* can be triggered by ferroptosis and lipopolysaccharides (LPS)-stimulated systemic inflammation in *vivo* can be partially blocked by inhibiting ferroptosis via Ferrostatin-1 treatment (Cui et al., 2021). Interestingly, multiple publications suggested ferroptosis resistance of microglia. Pro-inflammatory microglia display higher ferroptosis resistance than alternatively activated anti-inflammatory ones highly likely due to their abundant expression of NRF2 and enrichment of INOS/NO• (Jhelum et al., 2020; Kapralov et al., 2020). Pro-inflammatory microglia, but not anti-inflammatory ones, promote distant suppression of ferroptosis, implying anti-ferroptotic effects of neuroinflammation. Therefore, the exact roles of ferroptosis in MS remain unclear.
Besides, literatures have implied the involvement of ferroptosis in the pathogenesis of other NDDs. For example, ferroptosis has been found in light-induced retinal degeneration and Ferrostatin-1 has been reported to protect retina against degeneration via elevating the expression of SLC7A11 and GPX4 protein expression and suppress neuroinflammation (Tang et al., 2021). However, the pathological roles of ferroptosis in these unmentioned NDDs remain vague, which requires further investigations to clarify.

Hence, ferroptosis has been emerged as a key contributor to the pathogenesis of various NDDs. Given that, ferroptotic factors and ferroptosis-related signaling pathways have now been considered as potential diagnostic/prognostic biomarkers and therapeutic targets of NDDs. It is also worth-noting that ferroptosis has been reported to participate in neuroinflammation and neuronal death post-acute brain damage, which may play a role in the pathogenesis of NDDs as well (Mao et al., 2020; Cao et al., 2021; Cui et al., 2021; Ge et al., 2022; Qu et al., 2022).

**CONCLUSION**

In summary, NDDs are a group of pathologically and clinically heterogeneous diseases that create a heavy burden on healthcare systems, families, and individuals. However, the pathogenesis of NDDs has not been fully elucidated. To date, sufficient evidence has demonstrated that ferroptosis is closely related to the occurrence and progression of NDDs. The underlying mechanisms involve altered activities of Gpx4- and Nrf2-mediated signaling pathways, the deregulation of iron metabolism, oxidative distress, and glutamate-mediated excitotoxicity. In the future, more comprehensive investigations will greatly expand our understanding on the roles of ferroptosis in the pathogenesis of NDDs and shed light on the development of novel therapeutic technologies and strategies for treating incurable NDDs.

**AUTHOR CONTRIBUTIONS**

JL, JH, and JZ conceived the manuscript. YS and JL collected the references. YS, XX, DB, JL, and JH wrote the manuscript. All authors read and approved the final manuscript.

**FUNDING**

This work was supported in part by research grants from the National Natural Science Foundation of China (Nos. 82171194 and 81974155 to JL, Nos. 91949204 and 81830037 to JZ, Nos. 81971145 and 81901333 to XX) and by Biomedical Technology Support Project of Shanghai Science and Technology Commission (No. 22S31902600).

**ACKNOWLEDGMENTS**

We thank Qihui Wu for proofreading the manuscript.

**REFERENCES**

Agrawal, S., Fox, J., Thyagarajan, B., and Fox, J. H. (2018). Brain mitochondrial iron accumulates in Huntington’s disease, mediates mitochondrial dysfunction, and can be removed pharmacologically. *Free Radic. Biol. Med.* 120, 317–329. doi: 10.1016/j.freeradbiomed.2018.04.002

Al-Chalabi, A., Choi, A., Merrill, C., Oster, G., Bornheimer, R., Agnese, W., et al. (2021). Clinical staging in amyotrophic lateral sclerosis: analysis of Edaravone Study 19. *J. Neurol. Neurosurg. Psychiatry* 92, 165–171. doi: 10.1136/jnnp-2020-332371

Altamura, S., and Muckenthaler, M. U. (2009). Iron toxicity in diseases of aging: Alzheimer’s disease, Parkinson’s disease and atherosclerosis. *J. Alzheimers Dis.* 16, 879–895. doi: 10.3233/jad-2009-1010

Andrich, J., Saft, C., Gerlach, M., Schneider, B., Arz, A., Kuhn, W., et al. (2004). Coenzyme Q10 serum levels in Huntington’s disease. *J. Neural Transm. Suppl.* 68, 111–116. doi: 10.1007/978-3-7909-0579-9_13

Angelova, P. R., Choi, M. L., Berezhnov, A. V., Horrocks, M. H., Hughes, C. D., De, S., et al. (2020). Alpha synuclein aggregation drives ferroptosis: an interplay of iron, calcium and lipid peroxidation. *Cell Deathiffer.* 27, 2781–2796. doi: 10.1084/s14148-020-0542-z

Anthonymuthu, T. S., Tyurina, Y. Y., Sun, W. Y., Mikulsa-Ruminska, K., Shrivastava, I. H., Tyurin, V. A., et al. (2021). Resolving the paradox of ferroptotic cell death: Ferrostatin-1 binds to 15LOX/PEBP1 complex, suppresses generation of peroxidized ETE-PE, and protects against ferroptosis. *Redox Biol.* 38:101744. doi: 10.1016/j.redox.2020.101744

Ashraf, A., Jeandriens, J., Parkes, H. G., and So, P. W. (2020). Iron dyshomeostasis, lipid peroxidation and perturbed expression of cystine/glutamate antiporter in Alzheimer’s disease: evidence of ferroptosis. *Redox Biol.* 32:101494. doi: 10.1016/j.redox.2020.101494

Ayton, S., Diouf, I., and Bush, A. I. (2018). Evidence that iron accelerates Alzheimer’s pathology: a CSF biomarker study. *J. Neurol. Neurosurg. Psychiatry* 89, 456–460. doi: 10.1136/jnnp-2017-316551

Ayton, S., Faux, N. G., and Bush, A. I. (2015). Ferritin levels in the cerebrospinal fluid predict Alzheimer’s disease outcomes and are regulated by APOE. *Nat. Commun.* 6:7670. doi: 10.1038/ncomms7670

Ayton, S., Wang, Y., Diouf, I., Schneider, J. A., Brockman, J., Morris, M. C., et al. (2020). Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology. *Mol. Psychiatry* 25, 2932–2941. doi: 10.1038/s41380-019-0375-7

Bai, Y., Meng, L., Han, L., Jia, Y., Zhao, Y., Gao, H., et al. (2019). Lipid storage and lipophagy regulates ferroptosis. *Biochem. Biophys. Res. Commun.* 508, 997–1003. doi: 10.1016/j.jbrc.2018.12.039

Baloni, P., Funk, C. C., Readhead, B., and Price, N. D. (2021). Systems modeling of metabolic dysregulation in neurodegenerative diseases. *Curr. Opin. Pharmacol.* 60, 59–65. doi: 10.1016/j.coph.2021.06.012

Bao, W. D., Pang, P., Zhou, X. T., Hu, F., Xiong, W., Chen, K., et al. (2021). Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer’s disease. *Cell Deathiffer.* 28, 1548–1562. doi: 10.1084/s14148-020-00685-9

Basambombo, L. L., Carmichael, P. H., Cote, S., and Laurin, D. (2017). Use of vitamin E and C supplements for the prevention of cognitive decline. *Ann. Pharmacother.* 51, 118–124. doi: 10.1177/1060028016673072

Bellezza, I., Giambanco, I., Minelli, A., and Donato, R. (2018). Nrf2-Keap1 signaling in oxidative and reductive stress. *Biochim. Biophys. Acta Mol. Cell Res.* 1865, 721–733. doi: 10.1016/j.bbamcr.2018.02.010

Bellinger, F. P., Bellinger, M. T., Seale, L. A., Takemoto, A. S., Raman, A. V., Miki, T., et al. (2011). Glutathione peroxidase 4 is associated with neutromelanin in substantia nigra and dystrophic axons in putamen of Parkinson’s brain. *Mol. Neurodegener.* 6:8. doi: 10.1186/1750-1326-6-8
Bersuker, K., Hendricks, J. M., Li, Z., Magtanong, L., Ford, B., Tang, P. H., et al. (2019). The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. *Nature* 575, 688–692. doi: 10.1038/s41586-019-1705-2

Bracu, C., Zanoaga, O., Zimta, A. A., Tigu, A. B., Kilpatrick, K. L., Bishayee, A., et al. (2022). Natural compounds modulate the crosstalk between apoptosis and autophagy-regulated signaling pathways: controlling the uncontrolled expansion of tumor cells. *Semin. Cancer Biol.* 80, 218–236. doi: 10.1016/j.semcancer.2020.05.015

Brown, R. H., and Al-Chalabi, A. (2017). Amyotrophic lateral sclerosis. *Nature. J. Med.* 377, 162–172. doi: 10.1056/NEJMra1603471

Campanella, A., Rovelli, E., Santambrogio, P., Cozzi, A., Taroni, F., and Brown, R. H., and Al-Chalabi, A. (2017). Amyotrophic lateral sclerosis. *Nature Med.* 23, 461–491. doi: 10.1038/nj.2016.12892

D’Arcy, M. S. (2019). Cell death: a review of the major forms of apoptosis, necrosis and autophagy. *Cell Biol. Int.* 43, 582–592. doi: 10.1002/cbin.11137

Demarco, B., Chen, K. W., and Broz, P. (2020). Cross talk between intracellular pathogens and cell death. *ImmunoL. Rev.* 297, 174–193. doi: 10.1111/imr.12892

Derry, P. J., Hegde, M. L., Jackson, G. R., Kayed, R., Tour, J. M., Tsai, A. L., et al. (2020). Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s disease from a ferroptosis perspective. *Prog. Neurobiol.* 184:101716. doi: 10.1016/j.pneurobio.2019.101716

Devos, D., Cabantchik, Z. I., Moreau, C., Daniel, V., Mahoney-Sanchez, L., Bouchaoiu, H., et al. (2020). Conserved iron chelation for neurodegenerative diseases such as Parkinson’s disease and amyotrophic lateral sclerosis. *J. Neuro Transn.* 127, 189–203. doi: 10.1007/s00702-019-02138-1

Devos, D., Moreau, C., Kyheng, M., Garçon, G., Rolland, A. S., Blasco, H., et al. (2019). A ferroptosis-based panel of prognostic biomarkers for amyotrophic lateral sclerosis. *Sci. Rep.* 9:2918. doi: 10.1038/s41598-019-39739-5

Dias, V., Junn, E., and Mouradian, M. M. (2013). The role of oxidative stress in Parkinson’s disease. *J. Parkinsons Dis.* 3, 461–491. doi: 10.2233/jpd-130230

Diouf, I., Fazlollahi, A., Bush, A. L., and Ayton, S. (2019). Cerebrospinal fluid ferritin levels predict brain hypometabolism in people with underlying β-amyloid pathology. *Neurobiol. Dis.* 124, 335–339. doi: 10.1016/j.nbd.2018.12.010

Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., et al. (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. *Cell* 149, 1060–1072. doi: 10.1016/j.cell.2012.03.042

Dixon, S. J., Patel, D. N., Welsch, M., Skouta, R., Lee, E. D., Hayano, M., et al. (2014). Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. *eLife* 3:e02523. doi: 10.7554/eLife.02523

Eberhard, Y., McDermott, S. P., Wang, X., Gronda, M., Venugopal, A., Wood, T. E., et al. (2009). Chelation of intracellular iron with the antifungal agent ciclopirox olamine induces cell death in leukemia and myeloma cells. *Blood* 114, 3066–3073. doi: 10.1182/blood-2009-03-209963

Evans, R. C., Chen, L., Na, R., Yoo, K., and Ran, Q. (2022). The Gpx4AKO mouse is a versatile model for testing interventions targeting ferroptotic cell death of spinal motor neurons. *Neurotox Res.* 40, 373–383. doi: 10.1007/s12640-021-00469-0

Everett, J., Brooks, J., Lermeyte, F., O’Connor, P. B., Sadler, P. J., Dobson, J., et al. (2020). Iron stored in ferritin is chemically reduced in the presence of aggregating Aβ(1-42). *Sci. Rep.* 10:10332. doi: 10.1038/s41598-020-67117-z

Farr, A. C., and Xiong, M. P. (2021). Challenges and opportunities of ferroptosis delivery for treatment of Alzheimer's disease, Parkinson's disease, and intracerebral hemorrhage. *Mol. Pharm.* 18, 593–609. doi: 10.1021/acs.molpharmaceut.0c00474

Galluzzi, L., Kepp, O., Chan, F. K., and Kroemer, G. (2017). Necroptosis: mechanisms and relevance to disease. *Annu. Rev. Pathol. Biol.* 12, 103–130. doi: 10.1146/annurev-pathol-052016-100247

Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., et al. (2018). Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018. *Cell Death Diff.* 25, 486–541. doi: 10.1038/s41418-017-0012-4

Gammella, E., Recalcati, S., Rybinska, I., Buratti, P., and Cairo, G. (2015). Iron-sensitive and genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. *Cancer Cell* 37, 383–393. doi: 10.1016/j.ccell.2015-03-00050-3

Gao, M., Monian, P., Quadri, N., Ramasamy, R., and Jiang, X. (2015). Glutaminolysis and transferrin regulate ferroptosis. *Biochem. Biophys. Res. Commun.* 522, 966–971. doi: 10.1016/j.bbrc.2020.01.066

Gao, F., Li, J., Zhang, Y., and Chang, Y. Z. (2019). Cellular iron metabolism and regulation. *Adv. Exp. Med. Biol.* 1173, 21–32. doi: 10.1007/978-981-13-9589-5_2

Gao, J., Zhou, Q., Wu, D., and Chen, L. (2021). Mitochondrial iron metabolism and its role in diseases. *Clin. Chim. Acta* 513, 6–12. doi: 10.1016/j.cca.2020.12.005

Gao, M., Monian, P., Quadri, N., Ramasamy, R., and Jiang, X. (2015). Glutaminolysis and transferrin regulate ferroptosis. *Mol. Cell* 59, 298–308. doi: 10.1016/j.molcel.2015.06.011

Ge, H., Xue, X., Xian, J., Yuan, L., Wang, L., Zou, Y., et al. (2022). Ferrostatin-1 alleviates white matter injury via decreasing ferroptosis following spinal cord injury. *Mol. Neurobiol.* 59, 161–176. doi: 10.1007/s12035-021-02571-y
Guichardant, M., Chen, P., Liu, M., Calzada, C., Colas, R., Vérecel, E., et al. (2011). Functional lipidsomics of oxidized products from polyunsaturated fatty acids. Chem. Phys. Lipids 164, 544–548. doi: 10.1016/j.chemphysil.2011.05.002

Hadian, K., and Stockwell, B. R. (2020). SnapShot: ferroptosis. J. Neurochem. 133, 668–683. doi: 10.1111/jnc.13040

Hou, L., Huang, R., Sun, F., Zhang, L., and Wang, Q. (2019). NADPH oxidase regulates paracort and maneb-induced dopaminergic neurodegeneration through ferroptosis. Toxicology 417, 64–73. doi: 10.1016/j.tox.2019.02.001

Hu, C. L., Nydes, M., Shanley, K. L., Morales Pantoja, I. E., Howard, T. A., Hou, L., Huang, R., Sun, F., Zhang, L., and Wang, Q. (2019). NADPH oxidase regulates paracort and maneb-induced dopaminergic neurodegeneration through ferroptosis. Toxicology 417, 64–73. doi: 10.1016/j.tox.2019.02.001

Jia, F., Song, N., Wang, W., Du, X., Chi, Y., and Jiang, H. (2018). High dietary iron exacerbates iron accumulation and iron-mediated oxidative stress in the brain of Parkinson’s disease patients. Brain Pathol. 28, 314–324. doi: 10.1111/bpat.12821

Kapralov, A. A., Yang, Q., Dar, H. H., Tyurina, Y. Y., Anthonymuthu, T. S., Jenner, P., Dexter, D. T., Sian, J., Schapira, A. H., and Marsden, C. D. (1992). Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. U. S. A. 89, 225–234. doi: 10.1073/pnas.89.1.225

Khan, I., Yousif, A., Chesnokov, M., Hong, L., and Chefez, I. (2021). A decade of cell death studies: breathing new life into necroptosis. Pharmacol. Ther. 220:107717. doi: 10.1016/j.pharmthera.2020.107717

Kosman, H., Faraji, N., Komaki, A., Shahidi, S., Etaee, F., Raoufi, S., et al. (2019). Investigation of protective effects of coenzyme Q10 on impaired synaptic plasticity in a male rat model of Alzheimer’s disease. Brain Res. Bull. 147, 14–21. doi: 10.1016/j.brainresbull.2019.01.025

Komatsu, M., Kurokawa, H., Waguri, S., Taguchi, K., Kobayashi, A., Ichimura, Y., et al. (2010). The selective autophagy substrate p62 activates the stress responsive transcription factor Nrf2 through inactivation of Keap1. Nat. Cell Biol. 12, 213–223. doi: 10.1038/ncl2021

Liu, Y., and Levine, B. (2015). Autosis and autophagic cell death: the dark side of apoptosis. Cell Death Differ. 22, 367–376. doi: 10.1038/cdd.2014.143

Lucchetti, C. F., Brück, W., Rodriguez, M., and Lassmann, H. (1996). Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 6, 259–274. doi: 10.1111/j.1750-3639.1996.tb08354.x

Lv, H., and Shang, P. (2018). The significance, trafficking and determination of labile iron in cytosol, mitochondria and lysosomes. Metallomics 10, 899–916. doi: 10.1039/c9mt00044k

Mabulajaran, U., Aich, J., Leishangthem, G. D., Sharma, S. K., Dinda, A. K., and Ghosh, B. (2009). Effects of vitamin E on mitochondrial dysfunction and asthma features in an experimental allergic murine model. J. Appl. Physiol. 107, 1285–1292. doi: 10.1152/japplphysiol.00459.2009
MacKenzie, E. L., Iwasaki, K., and Tsuji, Y. (2008). Intracellular iron transport and storage: from molecular mechanisms to health implications. Antioxid. Redox Signal. 10, 997–1030. doi: 10.1089/ars.2007.1893

Maloney-Sánchez, L., Bouchaoui, H., Aytou, S., Devos, D., Duce, J. A., and Devedjian, J. C. (2021). Ferroptosis and its potential role in the pathophysiology of Parkinson’s disease. Prog. Neurobiol. 196:1011890. doi: 10.1016/j.pneurobio.2020.1011890

Majerniková, N., den Dunnen, W. F. A., and Dolga, A. M. (2021). The potential of ferroptosis-targeting therapies for Alzheimer’s disease: from mechanism to transcriptomic analysis. Front. Aging Neurosci. 13:745046. doi: 10.3389/fnagi.2021.745046

Mao, C., Liu, X., Zhang, Y., Lei, G., Yan, Y., Lee, H., et al. (2021). DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature 593, 586–590. doi: 10.1038/s41586-021-03539-7

Mao, H., Zhao, Y., Li, H., and Lei, L. (2020). Ferroptosis as an emerging target in inflammatory diseases. Prog. Biophys. Mol. Biol. 155, 20–28. doi: 10.1016/j.pbiomolbio.2020.04.001

Martin-Bastida, A., Ward, R. J., Newbould, R., Piccini, P., Sharp, D., Kabba, C., et al. (2021). Iron chaperone functions of ferritin and ferroportin. J. Neuropsychiatry Clin. Neurosci. 10, 997–1030. doi: 10.1016/j.jnccn.2020.10.018

Matsuo, T., Adachi-Tominari, K., Sano, O., Kamei, T., Nogami, M., Ogi, K., et al. (2020). The elemental role of iron in DNA synthesis and repair. Metallomics 9, 1483–1500. doi: 10.1039/c7m00116a

Qu, W., Cheng, Y., Peng, W., Wu, Y., Rui, T., Luo, C., et al. (2022). Targeting iNOS alleviates early brain injury after experimental subarachnoid hemorrhage via promoting ferroptosis of M1 microglia and reducing neuroinflammation. Mol. Neurobiol. 59, 3124–3139. doi: 10.1007/s12052-022-02788-5

Qin, R., Li, Y., and Zhang, F. (2021). KEAP1-modifying small molecule reveals muted NRF2 signaling responses in neural stem cells from Huntington’s disease patients. Proc. Natl. Acad. Sci. U.S.A. 114, E4676–E4685. doi: 10.1073/pnas.1616493114

Raha, A. A., Vaishnav, R. A., Friedland, R. P., Boford, A., and Raha-Chowdhury, R. (2013). The systemic iron-regulatory proteins hepcidin and ferroportin are reduced in the brain in Alzheimer’s disease. Acta Neuropathol. Commun. 1:55. doi: 10.1186/2051-9338-1-55

Rao, S. S., Porbury, S. D., Lago, L., Bush, A. I., and Adlard, P. A. (2020). The iron chelator deferiprone improves the phenotype in a mouse model of tauopathy. J. Alzheimers Dis. 78:1783. doi: 10.3233/jad-209099

Reddy, P. H., and Shirende, U. P. (2012). Mutant huntingtin, abnormal mitochondrial dynamics, defective axonal transport of mitochondria, and selective synaptic degeneration in Huntington’s disease. Biochim. Biophys. Acta 1822, 101–110. doi: 10.1016/j.bbadis.2011.10.016

Ren, J. X., Sun, X., Yan, Z. N., Guo, Z. N., and Yang, Y. (2020). Ferroptosis in neurological diseases. Front. Cell Neurosci. 14:218. doi: 10.3389/fncel.2020.00214

Riederer, P., Monoranu, C., Strobel, S., Jordache, T., and Sian-Hülsmann, J. (2021). Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson’s disease. J. Neural Transm. 128, 1577–1598. doi: 10.1007/s00702-021-02414-z

Ross, C. A., and Tibrizi, S. J. (2011). Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 10, 83–98. doi: 10.1016/s1474-4422(10)70245-3

Saito, T., Hishahara, S., Iwahara, N., Emoto, M. C., Yokokawa, K., Suzuki, H., et al. (2019). Early administration of galantamine from preplaque stage suppresses oxidative stress and improves cognitive behavior in APPsw/P301A9 mouse model of Alzheimer’s disease. Free Radic. Biol. Med. 145, 20–32. doi: 10.1016/j.freeradbiomed.2019.09.014

Seibt, T. M., Proneth, B., and Conrad, M. (2019). Role of GPx4 in ferroptosis and its pharmacological implication. Free Radic. Biol. Med. 133, 144–152. doi: 10.1016/j.freeradbiomed.2018.09.014

Shao, L., Dong, C., Geng, D., He, Q., and Shi, Y. (2021). Ginkgolide B protects against cognitive impairment in senescence-accelerated P8 mice by mitigating oxidative stress, inflammation and ferroptosis. Biochim. Biophys. Res. Commun. 572, 1–7. doi: 10.1016/j.bbrc.2021.07.081

Shin, C. S., Mishra, P., Watrous, J. D., Carelli, V., D'Aurelio, J., Jain, M., et al. (2017). The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility. Nat. Commun. 8:15074. doi: 10.1038/ncomms15074

Skouta, R., Dixon, S. J., Wang, J., Dunn, D. E., Orman, M., Shimada, K., et al. (2012). Ferrostatins inhibit oxidative lipid damage and cell death in diverse disease models. J. Am. Chem. Soc. 136, 4551–4556. doi: 10.1021/ja411006a

Song, L. M., Xiao, Z. X., Zhang, N., Yu, X. Q., Cui, W., Xie, J. X., et al. (2021). Apoferritin improves motor deficits in MPTP-treated mice by mitigating brain iron metabolism and ferroptosis. iScience 10, 4551–4556. doi: 10.1021/ja411006a

Spasić, S., Nikolić-Kokić, A., Miletić, S., Oreščanin-Dušić, Z., Spasić, M. B., Bruguljević, D., et al. (2020). Edaravone may prevent ferroptosis in ALS. Curr. Drug Targets 21, 776–780. doi: 10.2174/1389450121666202213350

Sun et al. Ferroptosis in Neurodegenerative Diseases
of Huntington’s disease. *Free Radic. Biol. Med.* 49, 147–158. doi: 10.1016/j.frrb.2010.03.017

Stockwell, B. R. (2019). A powerful cell-protection system prevents cell death by ferroptosis. *Nature* 575, 597–598. doi: 10.1038/s41586-019-03145-8

Stockwell, B. R., Friedmann Angeli, J. P., Bayar, H., Bush, A. I., Conrad, M., Dixon, S. J., et al. (2017). Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. *Cell* 171, 273–285. doi: 10.1016/j.cell.2017.09.021

Stoyanovsky, D. A., Tyurina, Y. Y., Shrivastava, I., Bahr, I., Tyurin, V. A., Prokochenko, O., et al. (2019). Iron catalysis of lipid peroxidation in ferroptosis: regulated enzymatic or random free radical reaction? *Free Radic. Biol. Med.* 133, 153–161. doi: 10.1016/j.freeradbiomed.2018.09.008

Sun, X., Li, X., Jia, H., Wang, H., Shui, G., Qin, Y., et al. (2020). Nuclear factor E2-related factor 2 mediates oxidative stress-induced lipid accumulation in adipocytes by increasing adipogenesis and decreasing lipolysis. *Antioxid. Redox Signal.* 32, 173–192. doi: 10.1089/ars.2019.7769

Sun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., et al. (2016). Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. *Hepatology* 63, 173–184. doi: 10.1002/hep.28251

Tang, W., Guo, J., Liu, W., Ma, J., and Xu, G. (2021). Ferrostatin-1 attenuates ferroptosis and protects the retina against light-induced retinal degeneration. *Biochem. Biophys. Res. Commun.* 548, 27–34. doi: 10.1016/j.bbrc.2021.02.055

Tang, Y., Zhang, D., Gong, X., and Zheng, J. (2022). A mechanistic survey of Alzheimer’s disease. *Biophysics. Chem.* 281, 106735. doi: 10.1016/j.bpc.2021.106735

Tao, Y., Wang, Y., Rogers, I. T., and Wang, F. (2014). Perturbed iron distribution in Alzheimer’s disease serum, cerebrospinal fluid, and selected brain regions: a systematic review and meta-analysis. *J. Alzheimers Dis.* 42, 679–690. doi: 10.3233/JAD-140396

Tian, Y., Lu, J., Hao, X., Li, H., Zhang, G., Liu, X., et al. (2020). FTH1 inhibits ferroptosis through ferritinophagy in the 6-OHDA model of Parkinson’s disease. *Neurotherapeutics* 17, 1796–1812. doi: 10.1007/s13311-020-00929-z

Tiwari, S., Atluri, V., Kaushik, A., Yndart, A., and Nair, M. (2019). Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. *Int. J. Nanomedicine* 14, 5541–5554. doi: 10.2147/injn.s200490

Värsönen, B. F., Gray, E., Thompson, A. G., Ansorge, O., Anthony, D. C., Cowley, S. A., et al. (2016a). Non-neuronal cells in amyotrophic lateral sclerosis - from pathogenesis to biomarkers. *Nat. Rev. Neuro.17, 333–348. doi: 10.1038/s41582-021-00487-8

Vallerga, C. L., Zhang, F., Fowdar, J., McRae, A. F., Qi, T., Nabais, M. F., et al. (2020). Analysis of DNA methylation associates the cystine-glutamate antiporter SLC7A11 with risk of Parkinson’s disease. *Sci. Rep.* 10:607. doi: 10.3389/fneur.2019.00607

van Bergen, J. M., Hua, J., Unschuld, P. G., Lim, I. A., Jones, C. K., Margolis, J., et al. (2019). Iron catalysis of lipid peroxidation in ferroptosis: death by lipid peroxidation. *Biochim. Biophys. Acta.* 1865, 275–285. doi: 10.1016/j.bbapap.2019.04.003

Wieler, M., Gee, M., and Martin, W. R. (2015). Longitudinal midbrain changes in early Parkinson’s disease: iron content estimated from R2* /MRI. *Parkinsonism Relat. Disord.* 21, 179–183. doi: 10.1016/j.parkreldis.2014.11.047

Winters, E. K., Bharathi, B. S., Hatfield, D., Conrad, M., Brielmeier, M., and Schweizer, U. (2014). Cerebellar hypoplasia in mice lacking selenoprotein biosynthesis in neurons. *Cell. Trace. Biol. Res.* 158, 203–210. doi: 10.1016/j.bpr.2013.09.044

Wollmer, M., Zagydo, L. A., and Harris, N. S. (2014). The molecular biology of human iron metabolism. *Lab. Med.* 45, 92–102. doi: 10.1309/lm28g2jxwmhm

Wirth, E. K., Bharathi, B. S., Hatfield, D., Conrad, M., Brielmeier, M., and Schweizer, U. (2014). Cerebellar hypoplasia in mice lacking selenoprotein biosynthesis in neurons. *Cell. Trace. Biol. Res.* 158, 203–210. doi: 10.1016/j.bpr.2013.09.044

Wu, W., Li, P., and Li, J. (2012). Necroptosis: an emerging form of programmed cell death. *Crit. Rev. Oncol. Hematol.* 82, 249–258. doi: 10.1016/j.critrevonc.2011.08.004

Wyant, K. J., Ridder, A. J., and Dayalu, P. (2017). Huntington’s disease-update on treatments. *Carr. Neurol. Neurosci. Rep.* 17:33. doi: 10.1159/100011910-017-039-9

Xia, X., Wang, Y., and Zheng, J. (2021). COVID-19 and Alzheimer’s disease: how one crisis worsens the other. *Transl. Neurodegener.* 10:15. doi: 10.1186/s40035-021-00237-2

Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., et al. (2016). Ferroptosis: process and function. *Cell Death Differ.* 23, 369–379. doi: 10.1038/cdd.2015.158

Xu, X., Lai, Y., and Hua, Z. C. (2019). Apoptosis and apoptotic body: disease message and therapeutic target potentials. *Biosci. Rep.* 39:BSR20180992. doi: 10.1042/bsr20180992

Yang, J., Hu, S., Bian, Y., Yao, J., Wang, D., Liu, X., et al. (2021). Targeting cell death: pyroptosis, ferroptosis, apoptosis and necroptosis in osteoarthritis. *Front. Cell. Dev. Biol.* 9:789948. doi: 10.3389/fcell.2021.789948

Yang, L., Calingsan, N. Y., Wille, E. J., Cormier, K., Smith, K., Ferrante, R. J., et al. (2009). Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson’s and Huntington’s diseases. *J. Neurochem.* 109, 1427–1439. doi: 10.1111/j.1471-4159.2009.07547.x

Yang, W. S., Kim, K. J., Gaschler, M. M., Patel, M., Shchepinov, M. S., and Stockwell, B. R. (2016). Peroxidation of polyunsaturated fatty acids by lipoygenases drives ferroptosis. *Proc. Natl. Acad. Sci. U.S.A.* 113, E4966–E4975. doi: 10.1073/pnas.1603244113

Yang, W. S., Sribaramatnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., et al. (2014). Regulation of ferroptotic cancer cell death by GPX4. *Cell* 154, 317–331. doi: 10.1016/j.cell.2013.12.010

Yang, W. S., and Stockwell, B. R. (2016). Ferroptosis: death by lipid peroxidation. *Trends Cell Biol.* 26, 165–176. doi: 10.1016/j.tcb.2015.10.014

You, P., Li, X., Wang, Z., Wang, H., Dong, B., and Li, Q. (2021). Characterization of brain iron deposition pattern and its association with genetic risk factor
in Alzheimer’s disease using susceptibility-weighted imaging. Front. Hum. Neurosci. 15:654381. doi: 10.3389/fnhum.2021.654381
Yu, Y., Yan, Y., Niu, F., Wang, Y., Chen, X., Su, G., et al. (2021). Ferroptosis: a cell death connecting oxidative stress, inflammation and cardiovascular diseases. Cell Death Discov. 7:193. doi: 10.1038/s44120-021-00579-w
Zeineh, M. M., Chen, Y., Kitzler, H. H., Hammond, R., Vogel, H., and Rutt, B. K. (2015). Activated iron-containing microglia in the human hippocampus identified by magnetic resonance imaging in Alzheimer disease. Neurobiol. Aging 36, 2483–2500. doi: 10.1016/j.neurobiolaging.2015.05.022
Zhang, G., Zhang, Y., Shen, Y., Wang, Y., Zhao, M., and Sun, L. (2021). The potential role of ferroptosis in Alzheimer’s disease. J. Alzheimers Dis. 80, 907–925. doi: 10.3233/jad-201369
Zhang, P., Chen, L., Zhao, Q., Du, X., Bi, M., Li, Y., et al. (2020). Ferroptosis was more initial in cell death caused by iron overload and its underlying mechanism in Parkinson’s disease. Free Radic. Biol. Med. 152, 227–234. doi: 10.1016/j.freeradbiomed.2020.03.015
Zhang, X., Wu, S., Guo, C., Guo, K., Hu, Z., Peng, J., et al. (2022). Vitamin E exerts neuroprotective effects in pentylenetetrazole kindling epilepsy via suppression of ferroptosis. Neurochem. Res. 47, 739–747. doi: 10.1007/s11064-021-03483-y
Zhang, Y., Fan, D., Liu, X., Liu, X., He, J., Zhang, N., et al. (2020). hTBK1-c.978T>A mutation promotes the ferroptosis in NSC-34 cells via mediation of KEAP1/NRF2/p62 signaling. Am. J. Transl. Res. 12, 7386–7394.
Zhang, Y. H., Wang, D. W., Xu, S. F., Zhang, S., Fan, Y. G., Yang, Y. Y., et al. (2018). α-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice. Redox Biol. 14, 535–548. doi: 10.1016/j.redox.2017.11.001
Zhang, Z., Hou, L., Song, J. L., Song, N., Sun, Y. J., Lin, X., et al. (2014). Pro-inflammatory cytokine-mediated ferroportin down-regulation contributes to the nigral iron accumulation in lipopolysaccharide-induced Parkinsonian models. Neuroscience 257, 20–30. doi: 10.1016/j.neuroscience.2013.09.037
Zhao, Y., Lu, J., Mao, A., Zhang, R., and Guan, S. (2021). Autophagy inhibition plays a protective role in ferroptosis induced by alcohol via the p62-Keap1-Nrf2 pathway. J. Agric. Food Chem. 69, 9671–9683. doi: 10.1021/acs.jafc.1c03751
Zheng, J., and Conrad, M. (2020). The metabolic underpinnings of ferroptosis. Cell Metab. 32, 920–937. doi: 10.1016/j.cmet.2020.10.011
Zhu, Y., Wang, B., Tao, K., Yang, H., Wang, Y., Zhou, T., et al. (2017). Iron accumulation and microglia activation contribute to substantia nigra hyperechogenicity in the 6-OHDA-induced rat model of Parkinson’s disease. Parkinsonism Relat. Disord. 36, 76–82. doi: 10.1016/j.parkreldis.2017.01.003
Zilka, O., Poon, J. F., and Pratt, D. A. (2021). Radical-trapping antioxidant activity of copper and nickel Bis(thiosemicarbazone) complexes underlies their potency as inhibitors of ferroptotic cell death. J. Am. Chem. Soc. 143, 19043–19057. doi: 10.1021/jacs.1c08254

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Sun, Xia, Basnet, Zheng, Huang and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
GLOSSARY

4-HNE, 4-hydroxynonenal; 5-FU, 5-fluorouracil; 6-OHDA, 6-hydroxydopamine; AA, arachidonoyl; ACSL4, long-chain-fatty-acid-CoA; AD, Alzheimer's disease; ADA, adrenoyl; ALA, alpha-lipoic acid; ALS, amyotrophic lateral sclerosis; AKT, threonine protein kinase; AMPK, activated protein kinase; APP, amyloid precursor protein; ARE, antioxidant response element; ATG, autophagy-related; ATP, adenosine triphosphate; Aβ, amyloid β; Bax, Bcl2-associated X.

Bcl-2, B-cell lymphoma-2; BH2, dihydrobiotin; BH4, tetrahydrobiopterin; CDDO, 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid; c-IAP1/2, cellular inhibitor of apoptosis proteins 1/2; CIL56, caspase-independent lethal 56; CNS, central nervous system; CoA, coenzyme A; CoQ10, coenzyme Q10; CoQH2, reduced coenzyme Q; CSF, cerebrospinal fluid; Cu2+, diacytis (4-methyl-3-thiosemicarbazidonato) copper(II); CUL3, cullin 3; DA, dopaminergic; DAMPs, damage-associated molecular patterns; DCYTB, duodenal cytochrome b; DFO, deferoxamine; DEGs, differentially expressed genes; DFP, deferoxiprone; DGR, double-glycine repeat; DHFR, dihydrofolate reductase; DHO, dihydrorootate acid; DHODH, dihydrorootate dehydrogenase; DMT1, divalent metal transporters 1; DNA, deoxyribonucleic acid; Ecto-CRT, surface-exposed calreticulin; EAE, experimental autoimmune encephalomyelitis; ERK, extracellular signal-regulated kinase; ESRCT-III, endosomal sorting complex required for transport III; FASL, factor associated suicide ligend; Fe2+, ferrous iron; Fe3+, ferric iron; Fe–S, iron–sulfur clusters; FIN56, ferroptosis inducing 56; FINO3, 1,2-dioxolane; FPN, ferroportin; FSP1, ferroptosis suppressor protein 1; FTH, ferritin heavy chain; FTL, ferritin light chain; FmTm, mitochondrial ferritin; G6PD, glucose-6-phosphate dehydrogenase; GCH1, GTP cyclohydrolase-1; GLS2, glutaminase 2; GM/CSF, granulocyte macrophage colony-stimulating factor; GPX4, glutathione peroxidase 4; Gpx4NKO, Gpx4 neuron inducible knockout; GSDMD, gasdermin D; GSEA, gene set enrichment analysis; GSH, glutathione; GSS, glutathione synthase; GSSG, oxidized glutathione; H2O2, hydrogen peroxide; HD, Huntington's disease; HMGBl, high mobility group box 1 protein; HO-1, heme oxygenase 1; HOCl, hypochlorous acid; IAPs, the inhibitor of apoptosis proteins; IL-2/3/4, interleukin-2/3/4; ILP-2, inhibitor of apoptosis protein-like protein-2; IMM, inner mitochondrial membrane; IPF, isopentenyl transferase; IPP, isopentenyl pyrophosphate; IRE, iron-responsive element; IREB2, iron responsive element binding protein 2; IRF, iron-regulatory protein; Keap1, KELCH-ECH-associated protein 1; LIP, labile iron pool; LOOHs, lipid hydroperoxides; LOX, lipooxygenase; LPCAT3, lysophosphatidylcholine acyltransferase 3; LPS, lipopolysaccharides; MAPK, mitogen-activated protein kinase; MDA, malondialdehyde; MDM2, murine double minute protein 1; MDMX, murine double minute X; MeV A pathway, Mevalonate Regulation pathway; NAD(P)+, oxidized nicotinamide adenine dinucleotide (phosphate); NAD(P)H, reduced nicotinamide adenine dinucleotide (phosphate); NDI, reduced nicotinamide adenine dinucleotide; NDDs, neurodegenerative diseases; NFOs, neurofibrillary tangles; NLRP3, NLR family pyrin domain-containing protein 3; Nr2, nuclear factor 2-related erythroid factor 2; NSA, necrosulfonamide; NTBI, non-transferrin bound iron; OA, orotate; OH, hydroxyl radical; PARP-1, Poly (ADP-ribose) polymerase 1; PCBP1, poly(rC)-binding protein 1; PD, Parkinson's disease; PE, phosphatidylethanolamines; PE-AA, phosphatidylethanolamines-acharidonyl; PE-AA-OOH, hydroperoxides of phosphatidylethanolamines-archidonyl; PE-ADA, phosphatidylethanolamines-adrenoyl; PE-ADA-OOH, hydroperoxides of phosphatidylethanolamines-adrenoyl; PE-PEB1, phosphatidylethanolamine-binding protein 1; PI3K, phosphoinositide 3-kinase; PUFAs, polyunsaturated fatty acids; PUFA-PL, polyunsaturated acyl-tailed phospholipids; RCD, regulated cell death; RIP-1, receptor interacting protein-1; RIP-3, receptor interacting protein-1; ROS, reactive oxygen species; RSL3, RAS-selective lethal 3; SAS, sulfasalazine; SCARA5, scavenger receptor class A member 5; Sec, selenocysteine; SELC3A2, solute carrier family 3 member 2; SELC7A11, solute carrier family 7 member 11; SM-164, Smac mimetics-164; SOD1, superoxide dismutase; SN, substantia nigra; SP, senile plaques; SREBP3, sterol-regulatory element-binding proteins; STEAP3, six-transmembrane epithelial antigen of prostate 3; SW1, susceptibility-weighted imaging; TBL, transferrin-bound iron; TCA cycle, tricarboxylic acid cycle; Tf, transferrin; TIR, transferrin receptor 1; TGF-β, transforming growth factor beta; TRAIL, tumor necrosis factor-related apoptosis-inducing ligand; tRNA, transfer ribonucleic acid; UTR, untranslated region; VTPA, viruspike tumor-activable pyroptotic agent; XIAP, X-linked inhibitor of apoptosis; ZIP14, Zrt/Irt-related protein 14; ZIP8, Zrt/Irt-related protein 8; ZnO-NPs, zinc oxide nanoparticles; ZnPPIX, zinc protoporphyrin IX; α-Syn, α-synuclein; a-TOH, α-tocopherol; Δψm, mitochondrion membrane potential.